Non-alcoholic fatty liver disease. Nonalcoholic steatohepatitis (NASH)
Conditions
Interventions
Intervention 1: Intervention group: resistance training (8 exercises of the upper and lower body
12 weeks with a frequency of 3 sessions per week
intensity of 60-80% of one maximum repetition
8-12 repetitions in a set
60-90 seconds of rest between each set and movement) with Vitamin E usage (12 weeks of taking vitamin E soft gel
daily dose of 800 international units, which was taken in two doses of 400 units with dinner and lunch). Intervention 2: Intervention group: resistance training (similar to intervention 1) with placeb
the composition of the placebo was oral paraffin). Intervention 3: Intervention group: Vitamin E usage (similar to intervention 1). Intervention 4: Control group: Placebo usage (similar to interventio
Sponsors
Razi University of Kermanshah
Eligibility
Sex/Gender
Male
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Lack of suffering from diabetes, cirrhosis, hepatitis B, hepatitis C, autoimmune hepatitis, hemochromatosis, Wilson's disease, AIDS, and prostate diseases Lack of regular use of drugs that increase transaminase levels or cause NAFLD.(such as amiodarone, tamoxifen, irinotecan, aspirin, glucocorticoids, etc.) Body mass index equal to or more than 25 kilogram/meter square Lack of alcohol consumption exceeding 30 g/day for at least 3 consecutive months in the last 5 years Lack of regular physical activity participation in the last 6 months Lack of weight gain or weight loss fluctuations of 5 kg or more in the last 3 months Fatty liver diagnosis by ultrasonography (Grade 1 at least) Age 18-45 years
Exclusion criteria
Exclusion criteria: Having cardiovascular, kidney, and respiratory diseases Having joint-muscular injuries in the exercise groups Using medications to treat fatty liver, such as Livergol, vitamin E, and vitamin D, regularly
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C1q/TNF-Related Protein-2 (CTRP2). Timepoint: Before & after the intervention. Method of measurement: Elisa method using human CTRP2 kit in accordance with the manufacturer’s instructions.;C1q/TNF-Related Protein-9 (CTRP9). Timepoint: Before & after the intervention. Method of measurement: Elisa method using human CTRP9 kit in accordance with the manufacturer’s instructions.;Insulin resistance and sensitivity index. Timepoint: Before & after the intervention. Method of measurement: Using homeostasis model assessment of insulin resistance index (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI).;Atherogenic index. Timepoint: Before & after the intervention. Method of measurement: Using the atherogenic index of plasma (AIP).;Aspartate aminotransferase enzyme (AST). Timepoint: Before & after the intervention. Method of measurement: Using SGOT kit and automatic analyzers.;Alanine aminotransferase enzyme (ALT). Timepoint: Before & after the intervention. Method of measurement: Using SGPT kit and automatic analyzers. | — |
Secondary
| Measure | Time frame |
|---|---|
| Body weight. Timepoint: Before and after the intervention. Method of measurement: Digital scale.;Body mass index (BMI). Timepoint: Before and after the intervention. Method of measurement: Body mass divided by the square of the body height.;Body fat percent. Timepoint: Before and after the intervention. Method of measurement: Bioelectrical impedance method using body composition analyzer device.;The waist–hip ratio (WHR). Timepoint: Before and after the intervention. Method of measurement: Waist measurement divided by hip measurement.;White blood cell count. Timepoint: Before and after the intervention. Method of measurement: Using automated devices.;Lipid profile. Timepoint: Before and after the intervention. Method of measurement: Using relevant kits and automated analyzers.;Fasting blood insulin. Timepoint: Before and after the intervention. Method of measurement: Elisa method using human insulin kit in accordance with the manufacturer’s instructions.;Fasting Blood Sugar. Timepoint: Before and after the intervention. Method of measurement: Using glucose kit and automated analyzers. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactIrfan Varmazyar
Razi University of Kermanshah
Outcome results
None listed